NHS
South West
Genomic Laboratory Hub

Bristol Genetics Laboratory *T*: 0117 414 6168 / 6167 / 6174
SWGLHenquiries@nbt.nhs.uk
https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub

Pharmacogenomic Test Request

R454 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (*CYP2C19* genotyping to guide mavacamten dosing).

Patient first name										Hospital number	
Patient last name										External ID	
Date of Birth (*dd/mm/yyyy*)				Sex							
NHS number											
Sample ~ 2-4ml EDTA whole blood										Collection date/time	

Reports will be returned by email to the clinician & recipients specified below.

Clinician name
Hospital & department
Email

CONSENT: In submitting this sample, the clinician confirms that informed consent has been obtained for (a) testing and storage (b) the use of this sample and the information generated from it to be shared with members of the donor's family and their health professionals (if appropriate). The patient should be advised that the sample may be used anonymously for quality assurance and training purposes.

Signature: .....

Additional report recipients

Name	Email
Name	Email
Name	Email

Please return completed request form with sample to:
South West Genomics Laboratory Hub
Bristol Genetics Laboratory
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Test Eligibility

Testing is available to patients with:

1. Symptomatic obstructive hypertrophic cardiomyopathy who have a New York Heart Association class of 2 to 3 **AND**
2. are eligible for treatment with mavacamten in line with NICE TA 913 (where mavacamten is an add on to individually optimised standard care that includes beta blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated).

NICE guidance https://www.nice.org.uk/guidance/ta913